NCT07129915 Nudge-Based Shared Decision Making and Self-Management in Type 2 Diabetes: A Randomized Trial
| NCT ID | NCT07129915 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Yunxuan Li |
| Condition | Diabetes Mellitus, Type 2 |
| Study Type | INTERVENTIONAL |
| Enrollment | 250 participants |
| Start Date | 2025-11-01 |
| Primary Completion | 2026-05-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 250 participants in total. It began in 2025-11-01 with a primary completion date of 2026-05-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study aims to test whether a communication strategy called "linguistic nudging" can help doctors and patients with type 2 diabetes make better treatment decisions together, and whether this improves patients' ability to manage their condition. What will happen in the study? - 250 adults with type 2 diabetes from Xiang'an Hospital (Xiamen) will be randomly assigned to one of two groups: Intervention group:Doctors will receive special training in "linguistic nudging" techniques to encourage shared decision-making. Patients will use a mobile app to record medication preferences, and doctors will adjust advice based on these preferences. Control group:Patients will receive standard diabetes care without these additional strategies. \- All participants will be followed for 6 months. What is the study aiming to find out? The main goal is to see if patients in the intervention group: Better follow medication plans Improve blood sugar monitoring Have better blood sugar control Feel more satisfied with doctor-patient communication Why is this important? Good self-management is key to controlling diabetes, but many patients struggle with it. Effective communication during shared decision-making may empower patients to manage their condition day-to-day with greater confidence. Patient safety and rights: Participation is completely voluntary All personal information will be kept strictly confidential Medical support will be provided if any health problems occur during the study Participants may withdraw at any time This research has been approved by the Ethics Committee of Xiang'an Hospital (Approval date: October 2025).
Eligibility Criteria
Inclusion Criteria: * Confirmed diagnosis of type 2 diabetes * Age ≥ 18 years * Normal cognitive function (assessed by Mini-Cog score ≥ 3) * Basic smartphone operation ability (can independently use WeChat) * Willing to participate and sign informed consent Exclusion Criteria: * Severe acute complications (e.g., ketoacidosis, hyperosmolar coma) * Documented cognitive impairment (dementia, Alzheimer's, etc.) * Currently participating in other clinical trials * Life expectancy \< 6 months * Pregnancy or lactation
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07129915 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Diabetes Mellitus, Type 2. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07129915 currently recruiting?
Yes, NCT07129915 is actively recruiting participants. Contact the research team at wwei19742007@hotmail.com for enrollment information.
Where is the NCT07129915 trial being conducted?
This trial is being conducted at Xiamen, China.
Who is sponsoring the NCT07129915 clinical trial?
NCT07129915 is sponsored by Yunxuan Li. The trial plans to enroll 250 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.